Skip to content
Head to head

Korsana Biosciences vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: KRSA · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

KRSA +286.0%VRTX +18.7%
Korsana Biosciences edges it on the scoreable measures. Korsana Biosciences has the highest Quant Rating (100); Korsana Biosciences has done best over the past year (+278%).
KRSAVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price37.56515.02
Change today+5.95%-1.08%
1-year return+277.9%+22.0%
Market cap$1.71B$130.58B
52-week range7.19 – 59.36412.27 – 568.67
Valuation
P/E (TTM)-53.6633.14
P/E percentile, own 5-yr range51st99th
P/B4.376.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-0.7015.32
Net profit (TTM)$-31.88M$3.88B
Revenue (TTM)--$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin--33.1%
Net margin--30.7%
Free cash flow (TTM)--$3.20B
Provider cash-flow period date2025-12-302026-09-29
Ownership & sentiment
Institutional ownership69.1%96.8%
Insider activity (12mo)0 buy / 0 sell28 buy / 22 sell
Short interest (% of float)0.4%1.9%
Analyst consensus100% buy (6)95% buy / 5% hold (21)
Analyst price target$51 (+36%)$624 (+21%)
StockVane view
StockVane Quant RatingC (100)C (68)
Company
Employees196,400
Founded20241989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.